Gain Therapeutics, Inc. (GANX)

Gain Therapeutics, Inc., a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas in Switzerland, Spain, the United States, and Australia. The company's drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease. Its lead drug candidate is GT-02287, which is currently in a Phase 1b study for the treatment of Parkinson's disease with or without a GBA1 mutation. The company has various small molecule drug candidates, which are in the discovery, research, and preclinical stages for the treatment of dementia with Lewy bodies, Alzheimer's disease, and Gaucher's disease, lysosomal storage disorders, metabolic disorders, and solid tumors. Gain Therapeutics, Inc. was founded in 2017 and is based in Bethesda, Maryland.

Symbol: GANX
Exchange: Nasdaq
Sector: Healthcare
Industry: Biotechnology
Market cap: $79.75M
52 week range: 1.53 - 4.34

Valuation

Share price: $1.84 (close of 2026-09-23)
P/E (TTM): -3.68x
Price to book: 7.06x
Price to free cash flow: -4.21x
Enterprise value: $67.27M
Book value per share: $0.26

Price performance

Period	Change
1 day	0.00%
5 days	+7.60%
1 month	-8.46%
3 months	+3.95%
6 months	-2.65%
Year to date	-42.86%
1 year	+5.14%
3 years	-44.91%
5 years	-75.30%
All time	-84.92%

Profitability and growth

Return on equity: -108.60%
Return on assets: -88.35%
Return on capital employed: -96.12%
Net income growth: 1.23%
Free cash flow growth: 2.28%

Cash flow and balance sheet

Free cash flow yield (TTM): -23.77%
Current ratio: 4.36x
Net debt to EBITDA: 0.65x

Latest reported year

Period end: 2025-12-31
Fiscal year: 2025
EBITDA: $-18.62M
Net income: $-20.16M
Earnings per share: $-0.61
Research and development: $10.21M
Shares outstanding: 32.97M

Income statement by year

Period end	Revenue	Net income	EPS
2025-12-31	-	$-20.16M	$-0.61
2024-12-31	-	$-20.41M	$-0.89
2023-12-31	$55.18K	$-22.27M	$-1.71
2022-12-31	$132.64K	$-17.59M	$-1.48
2021-12-31	$133.93K	$-13.89M	$-1.37
2020-12-31	$28.88K	$-3.58M	$-1.33

Margins and returns by year

Period end	Net margin	Return on equity	Return on capital
2025-12-31	-	-108.60%	-
2024-12-31	-	-278.10%	-
2023-12-31	-40354.33%	-177.03%	-
2022-12-31	-13262.02%	-93.17%	-138.43%
2021-12-31	-10371.70%	-39.90%	-
2020-12-31	-12387.67%	-57.69%	-